A Study of LY3127804 in Participants With COVID-19

A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19

A randomized, double-blind, placebo-controlled, clinical trial of LY3127804 in participants who are hospitalized with pneumonia and presumed or confirmed COVID-19.

Inclusion Criteria:

• Are hospitalized with pneumonia, and presumed or confirmed COVID-19
• Are able and willing to give signed informed consent (legally authorized representative can provide informed consent if needed)

Exclusion Criteria:

• Female participants must not be pregnant and/or lactating
• Have Acute Respiratory Distress Syndrome (ARDS) or will require immediate intermittent mandatory ventilation (IMV), or are ineligible for IMV
• Have any concurrent serious medical condition (for example dialysis) or concomitant medication that would preclude participation in the study
• Are moribund irrespective of the provision of treatments
• Have a known history or show evidence of human immunodeficiency virus (HIV) and/or hepatitis
• Have recently undergone major surgery or central venous access device placement
• Have a significant bleeding disorder or active vasculitis
• Have experienced a thromboembolic event
• Have symptomatic congestive heart failure, or symptomatic or poorly controlled cardiac arrhythmia
• Have a serious, nonhealing wound, peptic ulcer, or bone fracture
• Have liver cirrhosis
• Have a known sensitivity to monoclonal antibodies (mAbs) or other therapeutic proteins
• Have a history of hypertensive crisis or hypertensive encephalopathy or current, poorly controlled hypertension